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Introduction
Diabetic nephropathy is the leading cause of end-stage kidney disease in the industrialised world (1) , diabetic retinopathy is the leading cause of blindness in the working-age population (2) , and diabetic neuropathy eventually affects up to 50% of patients with long-standing diabetes (3) . Microascular dysfunction contributes to the development and progression of each of these complications, with abnormal vascular haemodynamics and disturbed vascular permeability leading to clinically important excessive vessel leak, such as macular oedema and albuminuria (4) .
In recent years, there has been increasing interest in identifying factors that are endogenously produced within the vasculature, are activated or inhibited in diabetes, and therefore could afford protection against diabetic vasculopathy(5) and potentially be used alongside traditional treatments. These factors, such as activated protein C(6) modify the response of the vasculature to the environment, thereby protecting endothelial and other vascular cells from the diabetic milieu. Vascular Endothelial Growth Factor-A (hereafter "VEGF-A"), a family of secreted glycoprotein isoforms, has been suggested as such an endogenous protective factor (5, 7) . VEGF-A levels are dysregulated, and VEGF-A receptor pathways activated, in many dysfunctional vascular beds in diabetes (5) . In glomeruli, VEGF-A is predominantly produced by podocytes, and its actions on endothelial cells and podocytes have been described (8, 9) . Targeted, inducible genetic deletion of all VEGF-A isoforms from podocytes causes glomerular disease in healthy animals (10) , and accelerated nephropathy in diabetic animals (7) . Total glomerular VEGF-A levels decrease as diabetic nephropathy progresses in man (11) , and anti-VEGF-A antibodies induce proteinuria in humans (10) . VEGF-A is therefore considered to provide an endogenous "protective" signal that prevents apoptosis of vascular wall cells and hence progression of diabetic nephropathy However, upregulating specific VEGF-A isoforms, such as VEGF-A165a, can also accelerate diabetic nephropathy (12) . VEGF-A165a is a potent vasoactive agent, increasing vasodilation, vascular permeability and angiogenesis (13) , processes that can drive the adverse functional consequences of diabetic vasculopathy. An equilibrium between sufficient (protective) and excessive (damaging) levels of VEGF-A, or an appropriately-timed VEGF-A response, may underly this paradox. An alternative explanation, however, is that these protective and deleterious VEGF-A actions in diabetes could be specific to VEGF-A isoforms, where some VEGF-A isoforms (e.g. VEGF-A164a) are detrimental, and others confer protection (14, 15 ). An alternative VEGF-A isoform, VEGF-A165b, has recently been shown to confer benefit in other microvascular disease states (16) (17) (18) . We therefore tested the hypothesis that VEGF-A165b could act as a protective factor in diabetic nephropathy.
Results

VEGF-A165b is upregulated in humans with diabetic nephropathy and wellpreserved kidney function
In twelve patients with biopsy-confirmed diabetic glomerulosclerosis, expression of exon 5/7/8-containing VEGF-A isoform (i.e. VEGF-A165a + VEGF-A165b) mRNA was significantly reduced compared with five non-diabetic individuals (11.9±4.2 vs 80.0±42.3 pg/ug mRNA; p<0.05, unpaired t-test). When diabetic nephropathy was categorised as "early" with well preserved kidney function and low-grade proteinuria (creatinine 89±8 µmol/L; proteinuria 1.0±0.3g/L; n=5; supplementary table 1) or "late" with elevated creatinine and heavy proteinuria (serum creatinine 242±10 µmol/L; proteinuria 7.8±0.2g/L; n=7; supplementary table 1), clear differences in the expression of different VEGF isoforms were apparent (figure 1). Total VEGF-A165a + VEGF-A165b mRNA expression progressively declined from "early" to "late" diabetic nephropathy, predominantly due to decreased VEGF-A165a mRNA levels (figure 1A, B). However, whilst VEGF-A165b levels also decreased in "late" diabetic nephropathy (figure 1C), VEGF-A165b levels significantly increased ~6-fold in "early" diabetic nephropathy. Thus only those with "early" diabetic nephropathy exhibited an ~12-fold increase in VEGF-A165b as a proportion of total VEGF-A isoforms present in the kidney ( figure 1D ). Similar changes were observed in just the glomerular compartment (figure 1E) and at the protein level ( figure 1F ). On the basis of these observations, we hypothesised that increasing glomerular VEGF-A165b confers protection against diabetic nephropathy.
Podocyte-specific VEGF-A165b overexpression protects against diabetic nephropathy.
Streptozotocin (STZ)-induced diabetic wild-type and podocyte-specific VEGF-A165b -overexpressing mice (nephVEGF-A165b) (figure 2A) demonstrated equivalent hyperglycaemia (figure 2B). Albuminuria increased 10.8-fold in diabetic wild-type mice but only 2.2-fold in diabetic nephVEGF-A165b mice, a change that was not statistically significantly different from non-diabetic controls ( figure 2C ). The early diabetes-related rise in creatinine clearance in diabetic wild-type mice was also attenuated in diabetic nephVEGF-A165b mice (figure 2D). After 6 weeks of diabetes, VEGF-A165b-overexpressing mice also demonstrated less glomerular hypertrophy (figure 2E,F), less mesangial matrix expansion (figure 2G,H) and less glomerular basement membrane thickening (figure 2I,J).
Given that podocyte-specific overexpression of murine VEGF-A164a (podVEGFA164a) accelerates diabetic nephropathy (19) , and that nephVEGF-A165b overexpression can block inducible podVEGF-A164a-overexpression permeability changes in healthy mice (20) , we hypothesised that nephVEGF-A165b effects would be sufficiently robust to prevent the more aggressive form of nephropathy in diabetic podVEGF-A164a mice. Wild-type, single and double-transgenic nephVEGFA165b/podVEGF-A164a mice (figure 3A) all demonstrated equal hyperglycaemia 5 weeks after streptozotocin. Albuminuria increased a further 3-fold above diabetic wild-type littermate values after 1 week of VEGF-A165a induction in diabetic podVEGF-A164a mice, an effect completely blocked by co-overexpression of VEGFA165a with VEGF-A165b (figure 3B).
Systemic injections of VEGF-A165b protect against diabetic nephropathy.
Systemic injections of recombinant human VEGF-A165b protein ( rh VEGF-A165b) reduce angiogenesis-related cancer growth in mice without altering blood pressure, renal function or eliciting adverse effects (21) . We therefore assessed the efficacy of systemic rh VEGF-A165b injections in STZ-induced diabetes in DBA2J mice before and after the onset of diabetic nephropathy (figure 4A). After 2 weeks of consistent hyperglycaemia, low-dose 0.04µg/kg rh VEGF-A165b injections were inititated and continued until an approved study endpoint occurred (significant weight loss).
Equivalent blood glucose concentrations were observed in both treatment groups (figure 4B). rh VEGF-A165b injections consistently reduced urinary albumin:creatinine ratios in diabetic mice, and this effect persisted throughout the entire period of hyperglycaemia (figure 4C).
In a separate cohort of diabetic DBA2J mice, low (0.04µg/kg) or high dose (0.2µg/kg) systemic rh VEGF-A165b injections were initiated only after the onset of heavy albuminuria (12 wks post-STZ; figure 4D ). Notably, albuminuria in these different cohort of mice receiving systemic injections was 5-20-fold greater than in the above groups. Again, vehicle-and rh VEGF-A165b-treated diabetic mice had equivalent blood glucose concentrations. Urinary albumin:creatinine ratios continued to rise in vehicletreated diabetic DBA2J mice (figure 4E). Despite having the highest urine albumin:creatinine ratios at the start of rh VEGF-A165b treatment, no increase in albuminuria was observed in mice receiving 0.04µg/kg rh VEGF-A165b injections, and there was a reduction in albuminuria in mice receiving 0.2µg/kg rh VEGF-A165b ( figure   4E,F) . The rh VEGF-A165b-induced improvements in albuminuria were significant at both treatment doses (figure 4F). rh VEGF-A165b injections also improved diabetesinduced glomerular basement membrane thickening (figure 4G,H) but not mesangial matrix expansion.
Systemic injections of VEGF-A165b improve early albuminuria but not GFR in a type 2 diabetic nephropathy model.
The global increase in diabetic nephropathy is predominantly due to type 2 diabetes.
We therefore administered 8 weeks of systemic rh VEGF-A165b injections to obese db/db mice after the onset of hyperglycaemia but before the onset of albuminuria or decreased GFR (figure 5A). rh VEGF-A165b injections (0.2µg/kg) did not alter blood glucose or body weight (figure 5B), but significantly reduced albuminuria (p<0.05, figure 5C ). Despite this improvement in albuminuria, however, rh VEGF-A165b injections did not prevent the diabetes-related decline in creatinine clearance (figure 5D) in these mice. As in the type 1 diabetes model, we also assessed the efficacy of rh VEGF-A165b injections started after the onset of both albuminuria and decreased creatinine clearance (figure 5E). No progression of albuminuria was noted in these db/db mice after this time (figure 5F), and rh VEGF-A165b injections initiated at this later timepoint did not modify the pattern of albuminuria (figure 5F), prevent further loss of GFR (figure 5G) or decrease mesangial matrix expansion (figure 5H). figure 8C ). In keeping with the observed improvements in albuminuria, rh VEGF-A165b injections restored glomerular endothelial glycocalyx depth in diabetic mice to levels observed in healthy non-diabetic control animals ( figure 8C ). Loss of endothelial glycocalyx in diabetes, and restoration by rh VEGF-A 165 b, was confirmed by confocal imaging of viable, unfixed glomeruli in STZ-injected diabetic rats ( figure   9 ).
VEGF-
VEGF-A165b improves human diabetic glomerular function.
Animal models of diabetic nephropathy exhibit substantial differences from human disease. The functional benefits of VEGF-A165b observed in multiple diabetic animal models were therefore tested on diabetic human glomeruli as well. In humans, rats and mice, LPA/Vi was significantly higher in glomeruli harvested from diabetic kidneys (all p<0.05 vs non-diabetic controls, figure 109A ). In addition, either longterm podocyte-specific overexpression of h VEGF-A165b (mice) or acute incubation with rh VEGF-A165b (rats and humans) reversed this diabetes-related increase in glomerular permeability (all p<0.05 vs vehicle-incubated diabetic glomeruli), and restored glomerular permeability to levels observed in non-diabetic controls ( figure   109A ). In paired measurements of diabetic human glomeruli permeability before and after exposure to rh VEGF-A165b, incubation with rh VEGF-A165b also reduced glomerular LPA/Vi to normal values (figure 109B).
Discussion
We show here that increasing VEGF-A165b levels effectively improves a number of functional and histological features of diabetic nephropathy. It can do so locally (through podocyte-specific overexpression) and systemically (via repeated intraperitoneal injections). It can do so in the context of additional upregulation of VEGF-A164a and in nephropathy complicating models of both type 1 and and type 2 diabetes, and it can do so both before and after the onset of albuminuria. We further demonstrate that VEGF-A165b acts on glomerular permeability through VEGFR2 in glomerular endothelial cells, and reverses diabetes-induced damage to the glomerular endothelial glycocalyx. We also demonstrate changes in the balance of VEGF-Axxxa/VEGF-Axxxb isoforms in human diabetic nephropathy, that glomerular permeability is increased in diabetic human glomeruli, and that the direct effects of VEGF-A165b on the glomerular capillary wall observed in animal models of diabetic nephropathy are reproduced at a functional level in diabetic human glomeruli. Thus it appears that VEGF-A165b can provide the endogenous protective actions of VEGF-A in diabetic nephropathy, without driving the deleterious consequences that appear to be mediated via VEGF-A165a in diabetic nephropathy.
Despite improved control of systemic parameters in diabetes such as hyperglycaemia, hypertension and hyperlipidaemia, diabetic nephropathy remains the leading cause of end-stage kidney disease across the developed world and no specific treatment for diabetic nephropathy is available (1) . Recent developments have focussed on harnessing endogenous vasculoprotective factors that could provide additional and complementary benefits for patients with diabetes(5). VEGF-A has long been considered a critical component of the vascular complications of diabetes. VEGF-A is generated as two families of isoforms according to alternative splicing of the terminal exon, exon 8 (22) . The canonical, proangiogenic isoforms such as VEGF-A165a (VEGF-A164a in the mouse) are matched by a family of antagonistic isoforms (e.g. VEGF-A165b, generically termed VEGF-Axxxb where xxx is the number of amino acids they encode). These VEGF-Axxxb isoforms match the prosurvival and anti-apoptotic effects of angiogenic VEGF-A isoforms, but do not drive angiogenesis, do not cause sustained increases in permeability, do not cause vasodilatation and can prevent the angiogenic and pro-permeability effects of VEGF-A165a (20, 23) . VEGF-A164a is not an endogenous renoprotective factor in diabetes, since overexpressing VEGF-A164a in diabetic mice accelerates nephropathy (19) . Our studies demonstrate that the VEGF-A165b isoform confers benefit in diabetic nephropathy. This clarifies the previous paradox that both VEGF overexpression and depletion are detrimental in diabetic nephropathy. It is therefore not just a timely and appropriate level of total VEGF-A that regulates glomerular and kidney function in diabetic nephropathy, but an appropriate balance of isoforms, and specifically sufficient levels of the protective VEGF-A165b isoform.
This demonstration that VEGF-A165b is a protective isoform in kidney disease is consistent with a series of reports that non-specific inhibition of all VEGF isoforms, for example with anti-VEGF antibodies, results in proteinuria and overt renal disease (10) . Such strategies will deplete both VEGF-A isoform families, thereby removing the protective actions of VEGF-A165b from the glomerular capillary wall and eliciting renal dysfunction and disease. Comparable isoform-specific benefits of VEGF-A165b have also been reported in systemic sclerosis (17) and Denys-Drash syndrome (18) , ocular disease (16, 24) and cancer (25) . Agents capable of manipulating the balance of VEGF-A isoforms could therefore offer a therapeutic strategy in a number of important human diseases, including diabetic nephropathy (26) . We show here that diabetic patients with well preserved kidney function have increased VEGF-A165b levels relative to VEGF-A165a. Transgenic podocyte-specific VEGF-A165b overexpression is the most analagous experimental model of this human situation, and it is noteworthy that the local upregulation of VEGF-A165b was the most effective approach in preventing multiple physiological and histological changes of diabetic nephropathy. We hypothesise that patients capable of upregulating VEGF-A165b relative to VEGF-A165a, via the modifiable machinery that regulates alternative splicing of the VEGF-A gene (23, (26) (27) (28) (29) , may experience protection from progressive nephropathy in diabetes. How to manipulate this alternative splicing mechanism for therapeutic benefit requires further exploration.
VEGF-R2 mediates the major actions of VEGF-A family members, is indispensible for normal glomerular function (9) , and mediates the beneficial effects of VEGF-A165b observed here. VEGF-A165b and VEGF-A165a bind VEGF-R2 with equal affinity, but elicit different tyrosine residue phosphorylation patterns, different VEGF-R2/neuropilin-1 heterodimerisation patterns (30, 31) , and different downstream signalling pathways (30) , resulting in different migration, proliferation and cytoprotection behaviours in endothelial (and other) cell types (22, 24, 31) . The observation that selective VEGF-R2 blockade in diabetic animals worsened albuminuria and endothelial cell apoptosis(32) is consistent with blocking beneficial endogenous VEGF-A165b signalling in rodents. Despite appropriate positive controls, however, the coding sequence of the rodent homologue of VEGF-A165b has not yet been identified (33, 34) . In addition, the coding sequences for exon 8 of VEGF-A165a (exon 8a) and VEGF-A165b (exon 8b) are overlapping, hitherto preventing generation of a VEGF-A165b knockout mouse model. Importantly, systemic injections of VEGF-A165b in the type 1 diabetes model also decreased heavy albuminuria and improved some of the histological features of diabetic nephropathy, even when treatment was started after the onset of nephropathy as might be required in clinical practice. The importance of defects in glomerular permeability in animal models of early albuminuric diabetic nephropathy is contested (35, 36) . These studies confirm that at least some facets of glomerular structure (endothelial glycocalyx) and permeability (ultrafiltration coefficient) are abnormal in early albuminuric diabetic nephropathy, and that reversing these glomerular defects through VEGF-A165b administration improves glomerular structure/function, albuminuria and histology. This emphasizes the important link between changes in glomerular function and albuminuria in early diabetic nephropathy, without excluding the potential importance of diabetes-induced changes in other parts of the nephron(35-37). In the type 2 diabetes db/db mouse model, VEGF-A165b injections reduced early albuminuria, but did not preserve GFR nor modify outcomes when intiated after the onset of nephropathy. Whether greater VEGF-A165b efficacy in type 1 diabetes models represents differences in disease timecourse(4), pharmacokinetics or validity of the animal model(38, 39) is not clear.
In this type 2 diabetes model, however, albuminuria was relatively low in all animals, and after 3 months regressed rather than progressed with time.
VEGFR2 activated by VEGF-A165b was localised to the endothelium. Decreased glomerular endothelial fenestrations, as observed here, has also been reported in diabetic humans, and the possibility of an associated reduction in water permeability was considered(40). In fact, the opposite is the case -water permeability is increased in diabetic human glomeruli. Moreover, VEGF-A165b restored normal water permeability and decreased albuminuria but did not modify fenestral density, suggesting that an alternative endothelial structure may be physiologically important, In summary, we show here that VEGF-A165b is upregulated in diabetic patients whose kidney function is well preserved, and that when VEGF-A165b is administered through a variety of routes, confers functional and histological benefit in a series of animal models of diabetic nephropathy. VEGF-A165b also effectively restores the endothelial glycocalyx in diabetic nephropathy, and improves the permeability function of glomeruli from diabetic humans. VEGF-A165b therefore appears to exert important protective actions in diabetic nephropathy. 
Methods
Enzyme-linked immunosorbent assay (ELISA) of pan-VEGF & VEGF-A165b
Protein was isolated from human kidney tissues after being homogenised in RIPA neph h VEGF-A165b were generated on a C57Bl6 background, and diabetes induction with a moderate-dose streptozotocin regime (100 mg/kg for 3 consecutve days) was therefore required to elicit nephropathy in the littermate controls. After crossing neph h VEGF-A165b mice with pod-rTta:TetO-m VEGF-A164a mice (mixed strain background), the low-dose AMDCC streptozotocin protocol (50 mg/kg for 5 consecutve days) was used. DBA2J mice were also treated with the low-dose AMDCC streptozotocin protocol (50) to induce diabetes and associated nephropathy. db/db mice (BKS.Cg-+Lepr db /+Lepr db /OlaHsd) were purchased from Harlan Laboratories U.K., and fed a standard rodent diet. Diabetes was induced in rats with a single intravenous injection of streptozotocin (45mg/kg) (51). All animals were fasted for 4-6 hours prior to administration of streptozotocin. Recombinant human VEGF-A165b ( rh VEGF-A165b) for intraperitoneal injection was generated as previously described (30) , and was administered after confirmation of two consecutive readings of hyperglycaemia (>16 mmol).
Body weight and blood glucose (ACCU-CHEK Aviva, Roche) were monitored weekly starting 4 weeks after streptozotocin administration in mice, 1 week after administration of streptozotocin in rats, and starting from 6 weeks of age in db/db mice. Urine samples were collected by overnight housing in metabolic cages. Urinary albumin was quantified with albumin ELISA (Bethyl Laboratories, Inc.), and creatinine using an enzymatic spectrophotometric assay (Konelab T-Series 981845; Thermo Fisher Scientific). Urinary albumin:creatinine ratio was calculated as the quotient of albumin concentration and creatinine concentration. Creatinine clearance was calculated from the volume of urine produced in a timed collection, creatinine concentration in the same sample and creatinine concentration in blood harvested at culling. GFR was determined with FITC-Inulin injection in conscious mice prior to culling, in accordance with the AMDCC protocol (52).
Kidney cortex samples harvested immediately post-mortem were flash frozen, and 5-to 10μm sections cut using a rotary microtome. Sections were mounted onto glass slides and stained with haematoxylin and eosin using standard techniques. Images were captured using a DCN-100 digital imaging system (Nikon Instruments, Surrey, UK). Glomerular area was calculated from the glomerular outline. Separate sections were stained with 0.5% periodic acid, Schiff reagent and Mayer's haematoxylin. The proportion of the glomerulus positive for PAS stain was determined according to AMDCC protocols using Adobe Photoshop (R) software.
For standard transmission electron microscopy animals were flushed by transcardiac perfusion with Ringer solution and then fixed with 2.5% glutaraldehyde (± 1% alcian blue for endothelial glycocalyx labeling), and small pieces (0.5-to 1-mm diameter) of kidney cortex studies were rapidly excised and fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer (4°C), washed in 0.1 M cacodylate buffer, postfixed in 1% osmium tetroxide and washed in distilled water. Tissues were ethanol-dehydrated and embedded in an Araldite (Agar Scientific). 50-to 100-nm thick sections were stained with 3% (aqueous) uranyl acetate and Reynolds' lead citrate solution. Digital micrographs were taken on either a Phillips 100CS microscope or Tecnai T12 microscope at x940, x1250, and x6,200. Images of the glomerular capillary wall were blinded, and detailed measurements taken randomly using a pre-defined algorithm using Adobe Photoshop. A fixed digital grid was superimposed over the electron micrograph, and glycocalyx depth was measured at points of intersection between these fixed gridlines and the image of the glomerular capillary wall. In total, 1,696 randomised measurements of glycocalyx depth in 179 glomerular capillaries from 9 animals across the 3 experimental groups were made using this algorithm by a blinded observer, and all analyses were completed prior to unblinding. Endothelial fenestrae were also counted in the same images, and fenestral density was calculated as the percentage of GBM filtration surface covered by endothelial fenestrae.
Kidney samples for immunofluorescence studies were formalin-fixed and embedded in wax. 5μm sections were mounted onto glass slides and left to dry overnight at 37°C. Sections were then de-waxed and re-hydrated before staining using anti-VEGFR-2 1:50 (Cell Signaling) and anti-P-VEGFR-2 (Y-951) 10μg/ml (Santa Cruz). 
Glomerular permeability assay
Glomeruli were harvested from mouse, rat or human cortical renal tissue by differential sieving and the glomerular ultrafiltration coefficient (LPA: hydraulic conductivity-area product) measured using a validated oncometric assay as previously described (45). In brief, individual glomeruli were mounted on a holding pipette within a flow-controlled observation chamber by gentle aspiration. The perifusate surrounding the glomerulus was rapidly exchanged from incubating solution (1% bovine serum albumin (BSA) in HEPES Ringer) to 8% BSA-HEPES Ringer, thereby increasing the oncotic pressure outside the glomerular capillary wall relative to the glomerular capillary lumen. The consequent flux of water out of the glomerular capillaries results in a rapid reduction in glomerular volume, which was recorded continuously on video-camera and analysed off-line using Fiji software (55) with in-house macros (developed by K Arkill). Linear regression analysis was used to calculate the initial (<0.1s) rate of reduction of glomerular volume (JV) in response to the applied oncotic pressure gradient (), the quotient of which describes glomerular ultrafiltration coefficient (LPA). For incubation studies, glomeruli were incubated for 1 hour with appropriate agents: 1nM of rh VEGF-A165b (30) 
